BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $7,633,000 | -51.3% | 469,430 | -58.5% | 0.19% | -41.3% |
| Q4 2021 | $15,659,000 | +25.6% | 1,130,578 | +30.3% | 0.32% | +35.9% |
| Q3 2021 | $12,472,000 | +73.8% | 867,920 | +91.2% | 0.24% | +76.9% |
| Q2 2021 | $7,178,000 | +64.2% | 453,995 | +5.6% | 0.13% | +44.1% |
| Q1 2021 | $4,372,000 | – | 429,902 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 3,926,700 | $56,427,000 | 4.43% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $27,601,000 | 3.44% |
| HealthCor Management, L.P. | 3,849,470 | $55,317,000 | 2.39% |
| MPM BioImpact LLC | 704,767 | $10,128,000 | 1.57% |
| Baker Brothers Advisors | 12,710,818 | $182,654,000 | 0.80% |
| Bain Capital Public Equity Management II, LLC | 1,472,471 | $21,159,000 | 0.74% |
| Biondo Investment Advisors, LLC | 267,480 | $3,844,000 | 0.66% |
| North Star Investment Management Corp. | 442,900 | $6,364,000 | 0.52% |
| DOLIVER ADVISORS, LP | 100,000 | $1,437,000 | 0.48% |
| Lisanti Capital Growth, LLC | 219,450 | $3,153,000 | 0.46% |